RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ all doses risperidone depot ‐… compared with PLACEBO (very low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).
Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).
HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
CHLORPROMAZINE showed no clear difference in leaving the study early ‐ due to adverse effects (short term) compared with RESERPINE (moderate certainty).
FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty).